Gain Therapeutics Inc. reported its financial results for the third quarter of 2025 and provided a corporate update. The company completed enrollment in its Phase 1b study evaluating GT-02287 for Parkinson's Disease, with a total of 21 participants-surpassing the original target of 15. Of these, 16 have completed 90 days of dosing, and the remaining 5 are expected to finish in December 2025. The study includes patients with or without GBA1 mutations. Initial data presented from the Phase 1b study suggest GT-02287 may have a disease-slowing effect, as indicated by stabilization and improvement in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores after approximately 30 days of administration. The company also received approval from Australian health authorities to extend the Phase 1b study duration, allowing participants to continue treatment for up to 12 months. Approximately 80% of participants have either joined or expressed interest in the extension phase. Analysis of functional changes and biomarker activity at 90 days is expected to be available in the fourth quarter of 2025. Planning for a Phase 2 study is underway.